Aligos reports Q2 2026 results, pevifoscorvir sodium enrollment complete

Aligos Therapeutics reported business updates and second quarter 2026 financial results on August 6, 2026. The company said pevifoscorvir sodium, a potential first- or best-in-class small molecule CAM-E for chronic hepatitis B virus infection, holds Fast Track Designation from the FDA and now also Breakthrough Therapy Designation from China's National Medical Products Administration Center for Drug Evaluation.¹

Enrollment in the Phase 2 "B-SUPREME" study (NCT06963710) is complete, with 131 participants in the HBeAg-positive cohort (Part 1a) and 114 participants in the HBeAg-negative cohort (Part 2a).¹ Topline data for both cohorts are expected in late Q3 2027.¹

On the antisense program, Aligos said its partner Amoytop received IND approval in China for ALG-170675 and is expected to move it into a Phase 1 SAD/MAD study in healthy volunteers, followed by multiple-dose testing in HBV patients in China.¹ That IND approval triggered a $3 million milestone payment to Aligos, expected in Q3 2026.¹ Aligos said it has the potential to conduct its own Phase 2 study of the ASO in 2028, possibly combined with pevifoscorvir sodium.¹

On financials, cash, cash equivalents and investments totaled $30.4 million as of June 30, 2026, down from $77.8 million at year-end 2025.¹ This figure excludes a $25 million upfront payment from Amoytop received in July 2026.¹ Aligos said its cash position is expected to fund planned operations into the fourth quarter of 2026, per the company's stated funding outlook.¹ Net loss for the quarter was $1.5 million, or $(0.14) per share, compared with a $15.9 million loss, or $(1.53) per share, a year earlier.¹